Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

14.76 -0.16 (-1.07%)

Delayed Quote Updated: 12:28 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 05, 2025

From Pomerantz LLP

Via GlobeNewswire

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 04, 2025

Via Benzinga

What to Expect from Ultragenyx Pharmaceutical's Earnings ↗

August 04, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 01, 2025

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome

July 31, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

July 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks ↗

July 28, 2025

HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

July 28, 2025

From Pomerantz LLP

Via GlobeNewswire

Beyond The Numbers: 7 Analysts Discuss Ultragenyx Pharmaceutical Stock ↗

July 28, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

July 18, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst ↗

July 14, 2025

Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.

Via Benzinga

Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection ↗

July 14, 2025

The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer.

Via Investor's Business Daily

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 11, 2025

Via Benzinga

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

July 11, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Market Monitor News July 11 BMO (Airline stocks UP - Ultragenyx Pharmaceuticals DOWN) ↗

July 11, 2025

Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show.

Via Chartmill

Topics World Trade

Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views ↗

July 10, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

July 10, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 10, 2025

Via Benzinga

Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings ↗

July 10, 2025

Via Benzinga

Which stocks are experiencing notable movement on Thursday? ↗

July 10, 2025

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

US Stocks Mixed; Initial Jobless Claims Fall ↗

July 10, 2025

Via Benzinga

Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease ↗

July 10, 2025

The study will continue onto a third and final analysis toward the end of the year.

Via Investor's Business Daily

Thursday's session: gap up and gap down stocks ↗

July 10, 2025

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win ↗

July 10, 2025

Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

July 10, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.